Matt Blankenship, MD
Gastroenterology · Tulsa, OKNPI 1902950165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 628 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations.
Across 628 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$967
- Pfizer$864
- Gilead$542
- plus $4K from 34 others
What the payments were for
- Food & beverage$11,470100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 160 | $2,415 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 83 | $1,492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 63 | $1,317 |
| Johnson & Johnson | 57 | $967 |
| Pfizer | 44 | $864 |
| Gilead | 31 | $542 |
| Ferring Pharmaceuticals Inc. | 24 | $429 |
| Lilly USA, LLC | 17 | $403 |
| Regeneron Healthcare Solutions, Inc. | 13 | $303 |
| Sanofi | 14 | $248 |
| Boston Scientific | 3 | $239 |
| Olympus America Inc. | 12 | $203 |
| Bristol Myers Squibb | 11 | $201 |
| Ipsen Biopharmaceuticals, Inc | 11 | $186 |
| Aimmune Therapeutics, Inc. | 7 | $175 |
| Braintree Laboratories, Inc. | 7 | $164 |
| Daiichi Sankyo Inc. | 6 | $146 |
| QOL Medical, LLC | 7 | $137 |
| UCB, Inc. | 5 | $116 |
| Merck | 6 | $99 |
| Nestle Healthcare Nutrition Inc. | 6 | $96 |
| Ironwood Pharmaceuticals, Inc | 6 | $92 |
| Madrigal Pharmaceuticals | 4 | $90 |
| Ardelyx, Inc. | 5 | $89 |
| Medtronic | 2 | $83 |
| Alnylam Pharmaceuticals Inc. | 4 | $75 |
| Abbott | 1 | $61 |
| Boehringer Ingelheim | 3 | $47 |
| Redhill Biopharma Inc. | 2 | $33 |
| Amgen | 2 | $31 |
| Novo Nordisk | 2 | $29 |
| Biocon Biologics Inc | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Organon | 2 | $15 |
| Sandoz | 1 | $14 |
| Dova Pharmaceuticals | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$124
- GENERAL - THERAPIES$117
How this compares
$11,513 in reported general payments places this provider in the 80th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 15 | $362,338 |
| Humira(Cf) PenAdalimumab | 20 | $152,594 |
| CreonLipase/Protease/Amylase | 21 | $45,327 |
| LinzessLinaclotide | 55 | $43,892 |
| XifaxanRifaximin | 13 | $28,289 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 126 | $20,495 |
| Mesalamine | 39 | $7,498 |
| Dexlansoprazole DrDexlansoprazole | 23 | $7,193 |
| Mesalamine ErMesalamine | 22 | $6,525 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 23 | $3,107 |
| Balsalazide Disodium | 17 | $2,540 |
| Omeprazole | 169 | $2,523 |
| Colestipol Hcl | 33 | $2,050 |
| Budesonide DrBudesonide | 20 | $1,725 |
| Ursodiol | 17 | $1,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $542 | $362,33815 claims |
| AbbVieCreon, Linzess | $2,415 | $89,21976 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $1,492 | $31,39636 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $429 | $20,495126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Tulsa
- Jeffrey HuntTulsa$155K
- Harvey TatumTulsa$27K
- Roy ThompsonTulsa$16K
- Aaron FiekerTulsa$15K
- Vasudevan RaghuramanTulsa$14K
- William BriggsTulsa$14K
- Sheldon BergerTulsa$14K
- David MorrisTulsa$13K
- Patrick VolakTulsa$13K
- John HoodTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.